The Biomarkers Procalcitonin and S100β Ptotein in the Clinical and Laboratory Monitoring of Neonatal Critical Conditions

Objective: to determine quantitative changes in procalcitonin (PCT) and S100β protein in serum from newborn infants under the long-term intensive care in an intensive care unit in order to optimize managing the care. Subjects and methods. A study group prospectively included 69 critically ill neonates of more than 2 days of birth admitted to the neonatal intensive care unit. The levels of PCT (normal values Results. In critically ill neonates, both biomarkers were shown to be increased in most cases. The level of PCT varied from the normal values up to 72 ng/ml [mean 1.03 (range 0.36—3.92 ng)]. Mean level of S100β protein was 0.339 (range 0.234—0.481) ^g/l. Levels of PCT and S100β positively correlated (r=0.47; p<0.05). The infants with the increased baseline levels of PCT demonstrated significant reduction of the biomarker over time that was considered as the adequacy of performed antibiotic therapy. The highest S100β levels were recorded in premature babies with sepsis including those without significant perinatal lesion of the central nervous system (CNS). Unidirectional reduction was typical for both S100β and PCT levels. Combination of increased S100β serum concentration decreased PCT was a pattern of developing the periventricular leukomalacia. There was evidence for a direct relation of biomarker S100β? to the presence of convulsive syndrome (Kendal’s coefficient 0.36; p<0.05). Conclusion. Similarly to newborn infants with traumatic, hypoxic, and hemorrhagic CNS lesions, patients with infectious and septic pathology exhibited elevated S100β levels. Both biomarkers PCT and S100β are suggested to be included in a battery of clinical and monitoring tests to optimize treatment of high-risk neonates in the intensive care unit. Key words: newborn infants, premature infants, critical conditions, biomarkers, procalcitonin, S100β protein, laboratory monitoring, perinatal pathology, antibacterial therapy.

новорожденные, недоношенные, критические состояния, биомаркеры, прокальцитонин, белок S100β, лабораторный мониторинг, перинатальная патология, антибактериальная терапия.

1. Black R.E., Cousens S., Johnson H.L., Lawn J.E., Rudan I., Bassani D.G., Jha P., CampbellH., Walker C.F., Cibulskis R., Eisele T., Liu L., Mathers C.; Child Health Epidemiology Reference Group of WHO and UNICEF.Lancet.

2. Blencowe H., Cousens S., Mullany L.C., Lee A.C., Kerber K., Wall S., Darmstadt G.L., Lawn J.E.Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect.BMC Public Health.2011; 11 (Suppl 3): S11.

3. Rosenberg R.E., Ahmed A.S., Saha S.K., Chowdhury MA., AhmedS., Law PA., Black R.E., Santosham M., Darmstadt G.L.Nosocomial sepsis risk score for preterm infants in low-resource settings.J. Trop. Pediatr.2010; 56 (2): 82—89.

4. Bartels D.B., Schwab F., Geffers C., Poets C.F., Gastmeier P.Nosocomial infection in small for gestational age newborns with birth weight <1500 g: a multicentre analysis.Arch. Dis. Child Fetal Neonatal Ed.2007; 92 (6): F449—F453.

5. Becerra M.R., Tantalean J.A., Suarez VJ., Alvarado M.C., Candela J.L., Urcia F.C.Epidemiologic surveillance of nosocomial infections in a Pediatric Intensive Care Unit of a developing country.BMC Pediatr.2010; 10: 66.

6. Stocker M., Hop W.C., van Rossum A.M.Neonatal Procalcitonin Intervention Study (NeoPInS): Effect of Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: A multi-centre randomized superiority and non-inferiority Intervention Study.BMC Pediatr.2010; 10: 89.

7. Jacquot A., LabauneJ.M., Baum T.P., Putet G., Picaud J.C.Rapid quantitative procalcitonin measurement to diagnose nosocomial infections in newborn infants.Arch. Dis. Child Fetal Neonatal Ed.2009; 94 (5): F345—F348.

8. Клиническое применение прокальцитонина для диагностики и мониторинга сепсиса. Руководство BRAHMS. 2004: 24.

9. Lopez Sastre J.B., Solfs D.P., Serradilla V.R., Colomer B.F., Cotallo G.D.; Grupo de Hospitales Castrillo.Evaluation of procalcitonin for diagnosis of neonatal sepsis of vertical transmission.BMC Pediatr.2007; 7:

10. Brunkhorst F.M., Heinz U., Forycki Z.F.Kinetics of procalcitonin in iatro-genic sepsis.Intensive Care Med.1998; 24 (8): 888-889.

11. Gabay C., Kushner I.Acute-phase proteins and other systemic responses to inflammation.N. Engl. J. Med.1999; 340 (6): 448-454.

12. Joram N., Boscher C., Denizot S., Loubersac V., Winer N., RozeJ.C., Gras-Le Guen C.Umbilical cord blood procalcitonin and C-reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection.Arch. Dis. Child Fetal Neonatal Ed.2006; 91 (1): F65—F66.

13. Перепелица С.А., Голубев А.М., Мороз В.В., Алексеева С.В.Причины острой интернатальной и постнатальной гипоксии у новорожденных.Общая реаниматология.2012; 8 (6): 17—23.

14. Медведев М.И., Дегтярева М.Г., Горбунов А.В., Гребенникова О.В., Дуленков А.Б., Воронов В.В.Последствия перинатальных гипокси-чески-ишемических поражений головного мозга у доношенных новорожденных: диагностика и принципы восстановительного лечения.Педиатрия.2011; 90 (1): 66—70.

15. Lai M.C., Yang S.N.Perinatal hypoxic-ischemic encephalopathy.J. Biomed. Biotechnol.2011; 2011: 609813.

16. Володин Н.Н.Неонатология: Национальное руководство. М.: ГЭО-ТАР-Медиа; 2007: 848.

17. Allen K.A., Brandon D.H.Hypoxic ischemic encephalopathy: patho-physiology and experimental treatments.Newborn Infant Nurs. Rev.2011; 11 (3): 125—133.

18. Пальчик А.Б., Шабалов Н.П.Гипоксически-ишемическая энцефалопатия новорожденных: Руководство для врачей. СПб.: Питер; 2000: 224.

19. Ратнер А.Ю.Неврология новорожденных. Казань: изд-во Казанского ГУ; 1995: 367.

20. Martinez-Biarge M., Diez-Sebastian J., Kapellou O., Gindner D., Allsop J.M., Rutherford MA, Cowan F.M.Predicting motor outcome and death in term hypoxic-ischemic encephalopathy.Neurology.2011; 76 (24): 2055—2061.

21. Distefano G., Pratico A.D.Actualities on molecular pathogenesis and repairing processes of cerebral damage in perinatal hypoxic-ischemic encephalopathy.Ital. J. Pediatr.2010; 36: 63.

22. Deng W., Pleasure J., Pleasure D.Progress in periventricular leukomala-cia.Arch. Neurol.2008; 65 (10): 1291-1295.

23. Ricardo-Garcell J, Harmony T., Porras-Kattz E., Colmenero-Batallan M.J., Barrera-Resendiz J.E., Fernandez-Bouzas A., Cruz-Rivero E.Epileptic encephalopathy in children with risk factors for brain damage.Epilepsy Res. Treat.2012; 2012: 747565.

24. Thorngren-Jerneck K., Ailing C., Herbst A., Amer-Wahlin I., Marsal K.S100 Protein in serum as a prognostic marker for cerebral injury in term newborn infants with hypoxic ischemic encephalopathy.Pediatr. Res.2004; 55 (3): 406—412.

25. Gazzolo D., Frigiola A., Bashir M., Iskander I., Mufeed H., Aboulgar H., Venturini P., Marras M., Serra G., Frulio R., Michetti F., Petraglia F., Abella R., Florio P.Diagnostic accuracy of S100B urinary testing at birth in full-term asphyxiated newborns to predict neonatal death.PLoS One.2009; 4 (2): e4298.

26. Gazzolo D., Bruschettini M., Lituania M., Serra G., Bonacci W., Michetti F.Increased urinary S100B protein as an early indicator of intraven-tricular hemorrhage in preterm infants:correlation with the grade of hemorrhage.Clin. Chem.2001; 47 (10): 1836—1838.

27. Douglas-Escobar M., Weiss M.D.Biomarkers of hypoxic-ischemic encephalopathy in newborns.Front. Neurol.2012; 3: 144.

28. Giuseppe D., Sergio C., Pasqua B., Giovanni L.V., Salvatore C., Frigiola A., Petra H., Maurizio A.Perinatal asphyxia in preterm neonates leads to serum changes in protein S-100 and neuron specific enolase.Curr. Neurovasc. Res.2009; 6 (2): 110—116.

29. Перепелица С.А., Голубев А.М., Мороз В.В., Алексеева С.В., Мельниченко В.А.Воспалительные изменения в плаценте и бактериальная инфекция у недоношенных новорожденных c дыхательной недостаточностью.Общаяреаниматология.2012; 8 (3): 18—25.

30. Berger R.P., Adelson P.D., Pierce M.C., Dulani T., Cassidy L.D., Kochanek P.M.Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children.J. Neurosurg.2005; 103 (1 Suppl): 61—68.

31. Spapen H., Nguyen D.N., Troubleyn J., Huyghens L., Schiettecatte J.Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock.Crit. Care.2010; 14 (2): R54.

32. Белобородова Н.В., Дмитриева И.Б., Черневская Е.А.Диагностическая значимость белка S100B при критических состояниях.Общаяреаниматология.2011; 7 (6): 72—76.

33. Pfister D., Siegemund M., Dell-Kuster S., Smielewski P., Ruegg S., Strebel S.P., Marsch S.C., Pargger H., Steiner L.A.Cerebral perfusion in sepsis-associated delirium.Crit. Care.2008; 12 (3): R63.

34. Hamed S.A., Hamed E.A., Abdella M.M.Septic encephalopathy: relationship to serum and cerebrospinal fluid levels of adhesion molecules, lipid peroxides and S-100B protein.Neuropediatrics.2009; 40 (2): 66—72.

35. Hamed S.A., Hamed E.A., Zakary M.M.Oxidative stress and S-100B protein in children with bacterial meningitis.BMC Neurol.2009; 9: 51.

36. Аврущенко М. Ш., Мороз В.В., Острова И.В.Постреанимационные изменения мозга на уровне нейрональных популяций: закономерности и механизмы.Общая реаниматология.2012; 8 (4): 69—79.